Daewoong Pharma
KRX:069620

Watchlist Manager
Daewoong Pharma Logo
Daewoong Pharma
KRX:069620
Watchlist
Price: 182 700 KRW -1.08% Market Closed
Market Cap: 2.1T KRW

Daewoong Pharma
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Daewoong Pharma
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Daewoong Pharma
KRX:069620
Interest Income Expense
-â‚©30.6B
CAGR 3-Years
-88%
CAGR 5-Years
-98%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Interest Income Expense
-â‚©10.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Biopharmaceuticals Co Ltd
KRX:326030
Interest Income Expense
-â‚©50.4B
CAGR 3-Years
13%
CAGR 5-Years
-82%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Interest Income Expense
-â‚©16.8B
CAGR 3-Years
-14%
CAGR 5-Years
9%
CAGR 10-Years
N/A
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Interest Income Expense
â‚©6.1B
CAGR 3-Years
N/A
CAGR 5-Years
95%
CAGR 10-Years
14%
C
Caregen Co Ltd
KOSDAQ:214370
Interest Income Expense
-â‚©521.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Daewoong Pharma
Glance View

Market Cap
2.1T KRW
Industry
Pharmaceuticals

Daewoong Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2002-11-01. The firm's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The firm distributes its products in domestic and overseas markets.

Intrinsic Value
265 671.67 KRW
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Daewoong Pharma's Interest Income Expense?
Interest Income Expense
-30.6B KRW

Based on the financial report for Jun 30, 2025, Daewoong Pharma's Interest Income Expense amounts to -30.6B KRW.

What is Daewoong Pharma's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-98%

Over the last year, the Interest Income Expense growth was -142%. The average annual Interest Income Expense growth rates for Daewoong Pharma have been -88% over the past three years , -98% over the past five years .

Back to Top